Table 3.
Univariate and multivariate analysis of risk factors for overall survival.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | P–value | HR (95% CI) | P–value | |
| Age | 0.994 (0.971–1.017) | 0.598 | ||
| Sex (male) | 2.059 (0.507–8.369) | 0.313 | ||
| ECOG performance status (≥ 2) | 5.195 (2.247–12.008) | 0.001 | 3.805 (1.605–9.023) | 0.002 |
| NLR | 1.065 (1.025–1.107) | 0.001 | 1.059 (1.018–1.102) | 0.005 |
| Tumor location (middle & lower) | 1.135 (0.719–1.793) | 0.587 | ||
| Tumor differentiation | 1.076 (0.637–1.819) | 0.784 | ||
| cT stage (≥ cT3) | 1.872 (1.197–2.927) | 0.006 | 1.586 (1.004–2.504) | 0.048 |
| cN stage (≥ cN1) | 1.842 (1.090–3.113) | 0.023 | 1.354 (0.779–2.352) | 0.283 |
| Radiation dose (< 50Gy) | 1.862 (0.861–4.029) | 0.114 | ||
| Consolidation therapy (no) | 1.121 (0.714–1.760) | 0.619 | ||
| CCRT complication (yes) | 1.216 (0.803–1.841) | 0.355 | ||
| Pre-CCRT BMI (< 23 kg/m2) | 1.417 (0.944–2.126) | 0.093 | ||
| Post-CCRT BMI (< 23 kg/m2) | 1.431 (0.910–2.251) | 0.121 | ||
| BMI decrement | 1.058 (0.955–1.173) | 0.278 | ||
| Pre-CCRT sarcopenia | 1.273 (0.837–1.937) | 0.254 | ||
| Post-CCRT sarcopenia | 1.923 (1.183–3.127) | 0.007 | 1.651 (1.007–2.704) | 0.047 |
| SMI decrement | 1.049 (1.011–1.088) | 0.011 | 1.042 (1.001–1.086) | 0.046 |
HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group; NLR, Neutrophil / lymphocyte ratio; cT, clinical tumor; cN, clinical nodal; CCRT, concurrent chemo- and radiotherapy; BMI, body mass index; SMI, skeletal muscle index.